Integrating fragment assembly and biophysical methods in the chemical advancement of small-molecule antagonists of IL-2: An approach for inhibiting protein-protein interactions

Journal of Medicinal Chemistry

Volumn 47, Issue 12, 2004, Pages 3111-3130

  Raimundo, Brian C ^a   Oslob, Johan D ^a   Braisted, Andrew C ^a   Hyde, Jennifer ^a   McDowell, Robert S ^a   Randal, Mike ^a   Waal, Nathan D ^a   Wilkinson, Jennifer ^a   Yu, Chul H ^a   Arkin, Michelle R ^a  

^a Sunesis Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 [2,3 DICHLORO 4 [5 [1 [2 (2 GUANIDINO 4 METHYLPENTANOYLAMINO)ACETYL]PIPERIDIN 4 YL] 1 METHYL 1H PYRAZOL 3 YL]PHENOXYMETHYL]BENZOIC ACID TRIFLUOROACETATE; CARBOXYLIC ACID DERIVATIVE; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING SITE; BIOPHYSICS; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; HUMAN; HUMAN CELL; HYDROPHOBICITY; INHIBITION KINETICS; LIVER MICROSOME; MOUSE; NONHUMAN; PROTEIN PROTEIN INTERACTION; REACTION ANALYSIS; STEADY STATE; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ACETYLENE; ANIMALS; BENZENE DERIVATIVES; BINDING SITES; COMBINATORIAL CHEMISTRY TECHNIQUES; CRYSTALLOGRAPHY, X-RAY; DIPEPTIDES; HUMANS; HYDROPHOBICITY; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MICE; MODELS, MOLECULAR; PIPERIDINES; PYRAZOLES; RECEPTORS, INTERLEUKIN;

EID: 2542643984     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049967u     Document Type: Article

References (55)

1. Rubin, L. A.; Nelson, D. L. The Soluble Interleukin-2 Receptor: Biology, Function, and Clinical Application. Ann. Intern. Med. 1990, 113, 619-627.
2. Nelson, B. H.; Willerford, D. M. Biology of the Interleukin-2 Receptor. Adv. Immunol. 1998, 70, 1-81.
3. Waldmann, T. A.; Dubois, S.; Tagaya, Y. Contrasting Roles of Il-2 and Il-15 in the Life and Death of Lymphocytes: Implications for Immunotherapy. Immunity 2001, 14, 105-110.
4. Nelson, B. H. Interleukin-2 Signaling and the Maintenance of Self-Tolerance. Curr. Dir. Autoimmun. 2002, 5, 92-112.
5. Church, A. C. Clinical Advances in Therapies Targeting the Interleukin-2 Receptor. Q. J. Med. 2003, 96, 91-102.
6. Le Moine, A.; Goldman, M.; Abramowicz, D. Multiple Pathways to Allograft Rejection. Transplantation 2002, 73, 1373-1381.
7. Singh, V. K.; Mehrotra, S.; Agarwal, S. S. The Paradigm of Th1 and Th2 Cytokines: Its Relevance to Autoimmunity and Allergy. Immunol. Res. 1999, 20, 147-161.
8. Schreiber, S. L.; Crabtree, G. R. The Mechanism of Action of Cyclosporin a and Fk506. Immunol. Today 1992, 13, 136-142.
9. Masri, M. A. The Mosaic of Immunosuppressive Drugs. Mol. Immunol. 2003, 39, 1073-1077.
10. Berard, J. L.; Velez, R. L.; Freeman, R. B.; Tsunoda, S. M. A Review of Interleukin-2 Receptor Antagonists in Solid Organ Transplantation. Pharmacotherapy 1999, 19, 1127-1137.
11. Waldmann, T. A.; O'Shea, J. The Use of Antibodies against the Il-2 Receptor in Transplantation. Curr. Opin. Immunol. 1998, 10, 507-512.
12. Toogood, P. L. Inhibition of Protein-Protein Association by Small Molecules: Approaches and Progress. J. Med. Chem. 2002, 45, 1-16.
13. Berg, T. Modulation of Protein-Protein Interactions with Small Organic Molecules. Angew. Chem,. Int. Ed. 2003, 42, 2462-2481.
14. Cochran, A. G. Antagonists of Protein-Protein Interactions. Chem. Biol. 2000, 7, R85-94.
15. Gadek, T. R.; Nicholas, J. B. Small Molecule Antagonists of Proteins. Biochem. Pharmacol. 2003, 65, 1-8.
16. Arkin, M. R.; Wells, J. A. Small-Molecule Inhibitors of Protein-Protein Interactions: Advancing Towards the Dream. Nat. Rev. Drug Discovery 2004, in press.
17. Nakamura, C. E.; Abeles, R. H. Mode of Interaction of Beta-Hydroxy-Beta-Methylglutaryl Coenzyme a Reductase with Strong Binding Inhibitors: Compactin and Related Compounds. Biochemistry 1985, 24, 1364-1376.
18. Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. Nmr-Based Screening in Drug Discovery. Q. Rev. Biophys. 1999, 32, 211-240.
19. Fejzo, J.; Lepre, C. A.; Peng, J. W.; Bemis, G. W.; Ajay et al. The Shapes Strategy: An Nmr-Based Approach for Lead Generation in Drug Discovery. Chem. Biol. 1999, 6, 755-769.
20. Boehm, H. J.; Boehringer, M.; Bur, D.; Gmuender, H.; Huber, W.; et al. Novel Inhibitors of DNA Gyrase: 3d Structure Based Biased Needle Screening, Hit Validation by Biophysical Methods, and 3d Guided Optimization. A Promising Alternative to Random Screening. J. Med. Chem. 2000, 43, 2664-2674.
21. Liu, G.; Huth, J. R.; Olejniczak, E. T.; Mendoza, R.; DeVries, P. et al. Novel P-Arylthio Cinnamides as Antagonists of Leukocyte Function-Associated Antigen-1/Intracellular Adhesion Molecule-1 Interaction. 2. Mechanism of Inhibition and Structure-Based Improvement of Pharmaceutical Properties. J. Med. Chem. 2001, 44, 1202-1210.
22. Carr, R.; Jhoti, H. Structure-Based Screening of Low-Affinity Compounds. Drug Discovery Today 2002, 7, 522-527.
23. Erlanson, D. A.; Wells, J. A.; Braisted, A. C. Tethering: Fragment-Based Drug Discovery. Annu. Rev. Biophys. Biomol. Struct. 2004, 33, in press.
24. Hann, M. M.; Leach, A. R.; Harper, G. Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery. J. Chem. Inf. Comput. Sci. 2001, 41, 856-864.
25. Jahnke, W.; Florsheimer, A.; Blommers, M. J.; Paris, C. G.; Heim, J.; et al. Second-Site NMR Screening and Linker Design, Curr. Top Med. Chem. 2003, 3, 69-80.
26. Nienaber, V. L.; Richardson, P. L.; Klighofer, V.; Bouska, J. J.; Giranda, V. L.; et al. Discovering Novel Ligands for Macromolecules Using X-ray Crystallographic Screening. Nat. Biotechnol. 2000, 18, 1105-1108.
27. Maly, D. J.; Choong, I. C.; Ellman, J. A. Combinatorial Target-Guided Ligand Assembly: Identification of Potent Subtype-Selective C-Src Inhibitors. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 2419-2424.
28. Vetter, D. Chemical Microarrays, Fragment Diversity, Label-Free Imaging by Plasmon Resonance - a Chemical Genomics Approach. J. Cell Biochem. Suppl. 2002, 39, 79-84.
29. Hyde, J.; Braisted, A. C.; Randal, M.; Arkin, M. R. Discovery and Characterization of Cooperative Ligand Binding in the Adaptive Region of Interleukin-2. Biochemistry 2003, 42, 6475-6483.
30. Erlanson, D. A.; Braisted, A. C.; Raphael, D. R.; Randal, M.; Stroud, R. M.; et al. Site-Directed Ligand Discovery. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 9367-9372.
31. Tilley, J. W.; Chen, L.; Fry, D. C.; Emerson, S. D.; Powers, G. D.; et al. Identification of a Small Molecule Inhibitor of the Il-2/Il-2ralpha Receptor Interaction Which Binds to Il-2. J. Am. Chem. Soc. 1997, 119, 7589-7590.
32. Emerson, S. D.; Palermo, R.; Liu, C. M.; Tilley, J. W.; Chen, L.; et al. NMR Characterization of Interleukin-2 in Complexes with the Il-2ralpha Receptor Component, and with Low Molecular Weight Compounds That Inhibit the Il-2/Il-Ralpha Interaction. Protein Sci. 2003, 12, 811-822.
33. Arkin, M. R.; Mike, R.; Delano, W. L.; Hyde, J.; Luong, T. N. et al. Binding of Small Molecules to an Adaptive Protein: Protein Interface. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 1603-1608.
34. Arkin, M.; Lear, J. D. A New Data Analysis Method to Determine Binding Constants of Small Molecules to Proteins Using Equilibrium Analytical Ultracentrifugation with Absorption Optics. Anal. Biochem. 2001, 299, 98-107.
35. Thanos, C.; Randal, M.; Wells, J. A. Potent Small-Molecule Binding to a Dynamic Hot Spot on Il-2. J. Am. Chem. Soc. 2003, 125, 15280-15281.
36. Braisted, A. C.; Oslob, J. D.; Delano, W. L.; Hyde, J.; McDowell, R. S.; et al. Discovery of a Potent Small Molecule Il-2 Inhibitor through Fragment Assembly. J. Am. Chem. Soc. 2003, 125, 3714-3715.
37. Johnston, J. A.; Bacon, C. M.; Finbloom, D. S.; Rees, R. C.; Kaplan, D.; et al. Tyrosine Phosphorylation and Activation of Stat5, Stat3, and Janus Kinases by Interleukins 2 and 15. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 8705-8709.
38. McKay, D. B. Unraveling the Structure of Interleukin-2: Reply. Science 1992, 257, 412-413.
39. Mott, H. R.; Baines, B. S.; Hall, R. M.; Cooke, R. M.; Driscoll, P. C.; et al. The Solution Structure of the F42a Mutant of Human Interleukin 2. J. Mol. Biol. 1995, 247, 979-994.
40. Hajduk, P. J.; Gomtsyan, A.; Didomenico, S.; Cowart, M.; Bayburt, E. K.; et al. Design of Adenosine Kinase Inhibitors from the Nmr-Based Screening of Fragments. J. Med. Chem. 2000, 43, 4781-4786.
41. Bogan, A. A.; Thorn, K. S. Anatomy of Hot Spots in Protein Interfaces. J. Mol. Biol. 1998, 280, 1-9.
42. Lo Conte, L.; Chothia, C.; Janin, J. The Atomic Structure of Protein-Protein Recognition Sites. J. Mol. Biol. 1999, 285, 2177-2198.
43. Wells, J. A.; de Vos, A. M. Hematopoietic Receptor Complexes. Annu. Rev. Biochem. 1996, 65, 609-634.
44. Atwell, S.; Ultsch, M.; De Vos, A. M.; Wells, J. A. Structural Plasticity in a Remodeled Protein-Protein Interface. Science 1997, 278, 1125-1128.
45. DeLano, W. L.; Ultsch, M. H.; de Vos, A. M.; Wells, J. A. Convergent Solutions to Binding at a Protein-Protein Interface. Science 2000, 287, 1279-1283.
46. Ma, B.; Shatsky, M.; Wolfson, H. J.; Nussinov, R. Multiple Diverse Ligands Binding at a Single Protein Site: A Matter of Preexisting Populations. Protein. Sci. 2002, 11, 184-197.
47. Sundberg, E. J.; Mariuzza, R. A. Luxury Accommodations: The Expanding Role of Structural Plasticity in Protein-Protein Interactions. Structure Fold. Des. 2000, 8, R137-142.
48. Freire, E. The Propagation of Binding Interactions to Remote Sites in Proteins: Analysis of the Binding of the Monoclonal Antibody D1.3 to Lysozyme. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 10118-10122.
49. McGovern, S. L.; Helfand, B. T.; Feng, B.; Shoichet, B. K. A Specific Mechanism of Nonspecific Inhibition. J. Med. Chem. 2003, 46, 4265-4272.
50. McGovern, S. L.; Caselli, E.; Grigorieff, N.; Shoichet, B. K. A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening. J. Med. Chem. 2002, 45, 1712-1722.
51. Iyobe, A.; Uchida, M.; Kamata, K.; Hotei, Y.; Kusama, H. et al. Studies on New Platelet Aggregation Inhibitors 1. Synthesis of 7-Nitro-3,4-Dihydroquinoline-2(1H)-one Derivatives. Chem. Pharm. Bull. (Tokyo) 2001, 49, 822-829.
52. Klein, S. I.; Molino, B. F.; Czekaj, M.; Gardner, C. J.; Chu, V.; et al. Design of a New Class of Orally Active Fibrinogen Receptor Antagonists. J. Med. Chem. 1998, 41, 2492-2502.
53. Muller, S.; Liepold, B.; Roth, G. J.; Bestmann, H. J. An Improved One-Pot Procedure for the Synthesis of Alkynes from Aldehydes. Synlett 1996, 521-522.
54. Sauve, K.; Nachman, M.; Spence, C.; Bailon, P.; Campbell, E.; et al. Localization in Human Interleukin 2 of the Binding Site to the Alpha Chain (P55) of the Interleukin 2 Receptor. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 4636-4640.
55. Zurawski, S. M.; Vega, F., Jr.; Doyle, E. L.; Huyghe, B.; Flaherty, K.; et al. Definition and Spatial Location of Mouse Interleukin-2 Residues That Interact with Its Heterotrimeric Receptor. Embo J. 1993, 12, 5113-5119.